ClinicalTrials.gov
public full text
Public Domain
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
RATIONALE: Zoledronate may prevent bone loss associated with long term androgen deprivation therapy. It is not yet known whether zoledronate combined with calcium is more effective than calcium alone in preventing bone loss. PURPOSE: Randomized phase III trial to compare the effectiveness of zoledronate combined with calcium with that of calcium alone in preventing bone loss in patients with stage III or stage IV prostate cancer who have received long-term androgen deprivation therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Zoledronic acid enhances tumor growth and metastatic spread in a mouse model of jaw osteosarcoma#284144
- Amelioration of Cd-induced bone deterioration by orally administered calcium phosphate#269359
- Combination of blood and biphasic calcium phosphate microparticles for the reconstruction of large bone defects in dog: A pilot study#159356
- BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)#875552
- Incidental Coronary Calcification Quality Improvement Project#829160
Record · ID 893153
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive